- Home
- CELZ vs OGEN Comparison
CELZ vs OGEN Comparison
Compare CELZ & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELZ
- OGEN
- Stock Information
- Founded
- CELZ 1998
- OGEN 1996
- Country
- CELZ United States
- OGEN United States
- Employees
- CELZ N/A
- OGEN N/A
- Industry
- CELZ Biotechnology: Pharmaceutical Preparations
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- CELZ Health Care
- OGEN Health Care
- Exchange
- CELZ Nasdaq
- OGEN Nasdaq
- Market Cap
- CELZ 4.7M
- OGEN 4.5M
- IPO Year
- CELZ N/A
- OGEN N/A
- Fundamental
- Price
- CELZ $2.17
- OGEN $0.35
- Analyst Decision
- CELZ
- OGEN
- Analyst Count
- CELZ 0
- OGEN 0
- Target Price
- CELZ N/A
- OGEN N/A
- AVG Volume (30 Days)
- CELZ 23.2K
- OGEN 1.3M
- Earning Date
- CELZ 11-08-2024
- OGEN 11-13-2024
- Dividend Yield
- CELZ N/A
- OGEN N/A
- EPS Growth
- CELZ N/A
- OGEN N/A
- EPS
- CELZ N/A
- OGEN N/A
- Revenue
- CELZ $11,000.00
- OGEN N/A
- Revenue This Year
- CELZ N/A
- OGEN N/A
- Revenue Next Year
- CELZ N/A
- OGEN N/A
- P/E Ratio
- CELZ N/A
- OGEN N/A
- Revenue Growth
- CELZ N/A
- OGEN N/A
- 52 Week Low
- CELZ $1.96
- OGEN $0.25
- 52 Week High
- CELZ $10.28
- OGEN $7.74
- Technical
- Relative Strength Index (RSI)
- CELZ 37.43
- OGEN 53.14
- Support Level
- CELZ $1.96
- OGEN $0.32
- Resistance Level
- CELZ $2.50
- OGEN $0.45
- Average True Range (ATR)
- CELZ 0.20
- OGEN 0.04
- MACD
- CELZ 0.00
- OGEN 0.00
- Stochastic Oscillator
- CELZ 32.36
- OGEN 36.80
About CELZ Creative Medical Technology Holdings Inc.
Creative Medical Technology Holdings Inc is a biotechnology holding company focused on regenerative medicine. It is formed for the purpose of creating and licensing intellectual property in the area of amniotic fluid derived stem cells for therapeutic applications. Its core activity is stem cell research and the development of applications for use to treat male and female sexual dysfunction, infertility, miscarriages, and related issues.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.